Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• Maze Therapeutics, Inc. has received an average recommendation of "Buy" from nine analysts, with an average 1-year price objective of $33.83.
• Recent upgrades include Guggenheim raising their price target from $19.00 to $34.00 and JPMorgan Chase increasing theirs from $27.00 to $37.00.
• Insider activity includes Director Richard H. Scheller selling 20,744 shares at an average price of $22.37, totaling approximately $464,043.

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been assigned an average rating of "Buy" from the nine analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $33.8333.

A number of equities research analysts recently commented on the stock. Guggenheim lifted their price target on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a "buy" rating in a report on Monday, September 15th. Wall Street Zen raised shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price target on shares of Maze Therapeutics in a report on Thursday, September 18th. JPMorgan Chase & Co. lifted their price target on shares of Maze Therapeutics from $27.00 to $37.00 and gave the stock an "overweight" rating in a report on Monday, September 29th. Finally, BTIG Research lifted their price target on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a "buy" rating in a report on Friday, September 12th.

Maze Therapeutics Stock Performance

Shares of NASDAQ MAZE opened at $29.26 on Thursday. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $29.66. The stock's 50 day moving average price is $20.08 and its 200-day moving average price is $14.58.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the business's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Institutional Investors Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of MAZE. TRV GP IV LLC bought a new stake in Maze Therapeutics during the 1st quarter valued at $66,874,000. Frazier Life Sciences Management L.P. bought a new stake in Maze Therapeutics during the 1st quarter valued at $45,460,000. ARCH Venture Management LLC bought a new stake in Maze Therapeutics during the 1st quarter valued at $45,362,000. Matrix Capital Management Company LP bought a new stake in Maze Therapeutics during the 1st quarter valued at $27,373,000. Finally, Alphabet Inc. bought a new stake in Maze Therapeutics during the 1st quarter valued at $26,561,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.